Loading...
XSTO
XSPRAY
Market cap128mUSD
Jun 11, Last price  
33.00SEK
1D
2.80%
1Q
5.10%
IPO
0.00%
Name

XSpray Pharma AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.63%
Rev. gr., 5y
-47.34%
Revenues
0k
3,640,000792,000331,546277,000000000
Net income
-286m
L+58.92%
-12,091,000-4,097,000-13,198,387-23,098,000-45,837,000-52,303,000-96,702,000-130,267,000-179,667,000-285,523,000
CFO
-222m
L+9.39%
-12,964,000-1,744,000-11,039,934-17,746,000-34,237,000-47,792,000-51,607,000-110,179,000-203,275,000-222,367,000

Profile

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
URL
https://xspraypharma.com/
IPO date
Sep 28, 2017
Employees
26
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
81,982
42,779
141,352
Unusual Expense (Income)
NOPBT
(81,982)
(42,779)
(141,352)
NOPBT Margin
Operating Taxes
151
(17)
(1,403)
Tax Rate
NOPAT
(82,133)
(42,762)
(139,949)
Net income
(285,523)
58.92%
(179,667)
37.92%
(130,267)
34.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
236,520
298,446
100,761
BB yield
-17.22%
-28.06%
-8.31%
Debt
Debt current
101,113
4,861
1,566
Long-term debt
59,329
68,755
2,686
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(47,795)
(92,687)
(118,914)
Cash flow
Cash from operating activities
(222,367)
(203,275)
(110,179)
CAPEX
(4,380)
(54,103)
(128,286)
Cash from investing activities
(42,142)
(65,876)
(135,345)
Cash from financing activities
306,108
315,594
93,809
FCF
(34,821)
(104,654)
(159,952)
Balance
Cash
208,236
166,303
120,166
Long term investments
1,000
3,000
Excess cash
208,237
166,303
123,166
Stockholders' equity
(803,109)
(523,471)
(351,401)
Invested Capital
1,554,426
1,253,692
907,488
ROIC
ROCE
EV
Common stock shares outstanding
33,137
26,594
21,263
Price
41.45
3.63%
40.00
-29.82%
57.00
-11.08%
Market cap
1,373,541
29.12%
1,063,756
-12.23%
1,211,971
-2.60%
EV
1,325,746
971,069
1,093,057
EBITDA
(73,435)
(33,585)
(131,819)
EV/EBITDA
Interest
675
12
Interest/NOPBT